Innovative Trials – the UK-based global clinical trial patient recruitment, retention and engagement company – has opened its first international office in the US. The move signals its commitment to ...

The European Medicines Agency’s (EMA) committee for Medicinal Products for Human Use (CHMP) recommended 15 new medicines for approval in its final meeting of the year.

The University of Exeter and Medicines Discovery Catapult (MDC) have partnered to accelerate medicines research and development to maximise the impact and value of basic medical research.

The SPIKE1 trial, funded by LifeArc and a partnership between the charity’s Centre for Drug Development (CDD), Latus Therapeutics and the University of Edinburgh, will investigate whether camostat, ...

Roche’s Kadcyla (trastuzumab emtansine)should soon be available on the NHS as a treatment option for patients with HER2-positive early breast cancer having won the backing of the National Institute ...

AstraZeneca and MSD’s Lynparza (olaparib) has been cleared in the US for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.

The jointly-sponsored study aims to validate PredictSURE IBD – the company’s first prognostic test for inflammatory bowel disease, in the US market.

Janssen has announced new two-year data from the long-term extension of the Phase III UNIFI study, demonstrating the efficacy and safety of Stelara (ustekinumab) in moderately to severe ulcerative ...

Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations.

C4X Discovery has announced the formation of a new Drug Discovery Advisory Network, to be headed up by industry veteran Robin Carr, who has worked at GlaxoSmithKline (GSK) and Astex. The company has ...

Drug-resistant superbugs are on the rise worldwide and represent a threat to global public health and health security. Oxford Drug Design has received over £8 million in grant and equity investment ...

New data from a Phase III trial of AstraZeneca and MSD’s Lynparza (olaparib) has shown that 22% of patients receiving the monotherapy remained free of disease progression after two years vs. 10% on ...